All In Biotech

Drug Trial Radar · NCT04776252

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Sep 15, 2021

Primary completion

May 29, 2029

Study completion May 29, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (100mg) and islatravir (0.75mg) \[DOR/ISL 100 mg/0.75 mg) will be evaluated in participants with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier clinical studies.

Conditions

  • HIV-1 Infection

Interventions

  • MK-8591ADrug

    FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with serious adverse events (SAEs)Time frame: Up to Week 198
  2. Participants who discontinued due to an adverse event (AE)Time frame: Up to Week 192

Locations

93 sites in 16 countries. Site status is shown where the registry gives one.

  • Pueblo Family Physicians ( Site 0010)

    Phoenix, Arizona

  • One Community Health ( Site 0045)

    Sacramento, California

  • Whitman-Walker Institute ( Site 0039)

    Washington D.C., District of Columbia

  • Georgetown University Medical Center-Clinical Trials Unit Division of Infectious Diseases ( Site 002

    Washington D.C., District of Columbia

  • Midway Immunology and Research Center ( Site 0033)

    Ft. Pierce, Florida

  • Orlando Immunology Center ( Site 0017)

    Orlando, Florida

  • Bliss Healthcare Services-Research ( Site 0030)

    Orlando, Florida

  • Triple O Research Institute, P.A ( Site 0031)

    West Palm Beach, Florida

  • Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 0015)

    Savannah, Georgia

  • Northstar Healthcare ( Site 0003)

    Chicago, Illinois

  • KC CARE Health Center-Clinical Trials ( Site 0012)

    Kansas City, Missouri

  • ID Care ( Site 0028)

    Hillsborough, New Jersey

  • Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center ( Site 0006)

    New York, New York

  • Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site

    Philadelphia, Pennsylvania

  • St Hope Foundation ( Site 0041)

    Bellaire, Texas

  • North Texas Infectious Diseases Consultants, P.A-Research ( Site 0004)

    Dallas, Texas

  • Texas Center for Infectious Disease Associates-Clinical Research ( Site 0026)

    Fort Worth, Texas

  • The Crofoot Research Center ( Site 0008)

    Houston, Texas

  • Holdsworth House Medical Practice ( Site 0700)

    Darlinghurst, New South Wales, Australia

  • St Vincent's Hospital-IBAC ( Site 0702)

    Sydney, New South Wales, Australia

  • Fiona Stanley Hospital ( Site 0706)

    Murdock, Western Australia, Australia

  • Sheldon M. Chumir Health Centre-Southern Alberta Clinic ( Site 0106)

    Calgary, Alberta, Canada

  • Vancouver Infectious Diseases Centre ( Site 0100)

    Vancouver, British Columbia, Canada

  • Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 0109)

    Hamilton, Ontario, Canada

  • Maple Leaf Research ( Site 0105)

    Toronto, Ontario, Canada

  • Toronto General Hospital ( Site 0104)

    Toronto, Ontario, Canada

  • Clinique de médecine Urbaine du Quartier Latin ( Site 0110)

    Montreal, Quebec, Canada

  • Clinique Medicale lActuel ( Site 0108)

    Montreal, Quebec, Canada

  • Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0202)

    Temuco, Araucania, Chile

  • Biomedica Research Group-Infectology ( Site 0201)

    Santiago, Region M. de Santiago, Chile

  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 0204)

    Santiago, Region M. de Santiago, Chile

  • Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0200)

    Santiago, Region M. de Santiago, Chile

  • Fundacion Valle del Lili- CIC ( Site 0300)

    Cali, Valle del Cauca Department, Colombia

  • Hôpital Bichat - Claude-Bernard-infectious diseases ( Site 1523)

    Paris, France

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 1504)

    Nice, Alpes-Maritimes, France

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1516)

    Dijon, Bourgogne-Franche-Comté, France

  • CHU de Bordeaux Hop St ANDRE-Médecine interne et maladies infectieuses ( Site 1512)

    Bordeaux, Gironde, France

  • CHU de Toulouse-Infectious Disease-Tropical Diseases ( Site 1505)

    Toulouse, Haute-Garonne, France

  • CHU Charles Nicolle-Inefectious disease ( Site 1506)

    Rouen, Haute-Normandie, France

  • Hospital La Colombière ( Site 1518)

    Montpellier, Herault, France

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.